Edition:
United States

Guerbet SA (GRBT.PA)

GRBT.PA on Paris Stock Exchange

56.70EUR
23 May 2018
Change (% chg)

-- (--)
Prev Close
€56.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,859
52-wk High
€87.65
52-wk Low
€50.00

Chart for

About

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents... (more)

Overall

Beta: 0.43
Market Cap(Mil.): €701.31
Shares Outstanding(Mil.): 12.50
Dividend: 0.85
Yield (%): 1.52

Financials

  GRBT.PA Industry Sector
P/E (TTM): 15.37 28.66 32.90
EPS (TTM): 3.65 -- --
ROI: 6.63 13.20 12.74
ROE: 14.07 14.95 14.64

BRIEF-Guerbet Announces Acquisition Of A New Microsphere Technology

* GUERBET ANNOUNCES THE ACQUISITION OF A NEW MICROSPHERE TECHNOLOGY TO STRENGTHEN ITS INTERVENTIONAL IMAGING RANGE

Apr 26 2018

BRIEF-Guerbet Expects 2018 Revenue In-Line With 2017

* FOR 2018, EXPECTS REVENUE IN-LINE WITH 2017 AT CONSTANT EXCHANGE RATES

Apr 18 2018

BRIEF-Guerbet Q1 Revenue Stable At 196.5 Million Euros

* Q1 REVENUE EUR 196.5 MILLION VERSUS EUR 197.3 MILLION YEAR AGO

Apr 18 2018

BRIEF-Guerbet Partners With Lausanne’S CHUV And CET To Launch Clinical Study

* PARTNERS WITH LAUSANNE’S CHUV AND CET TO LAUNCH A CLINICAL STUDY

Apr 13 2018

BRIEF-Guerbet FY EBITDA Increased By 22.4 Percent To 130 Million Euros

* FY NET INCOME EUR 46.2 MILLION VERSUS EUR 28.9 MILLION YEAR AGO

Mar 27 2018

BRIEF-Guerbet: FY Revenue At Constant Exchange Rates Increases To 812.4 Million Euros

* REG-GUERBET : 2017 REVENUE AT CONSTANT EXCHANGE RATES: €812.4 MILLION; +4.7%

Feb 15 2018

BRIEF-Guerbet Updates On MHLW Decision In Japan

* HAS IMMEDIATELY PROCEEDED TO REQUESTED REVISION OF PRECAUTIONS FOR MAGNESCOPE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Dec 06 2017

Earnings vs. Estimates